Cure My Disease

Don't miss your cure!

 Log in / Sign up

New prostate cancer combo aims to outperform standard therapy

NCT ID NCT07241416

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated May 13, 2026 · Updated 22 times

Summary

This phase 3 trial tests whether a new drug called rezvilutamide, combined with hormone therapy, works better than the current standard enzalutamide plus hormone therapy for men with low-volume metastatic hormone-sensitive prostate cancer. About 206 participants will receive one of the two treatments. The main goal is to see if rezvilutamide can lower PSA levels more effectively within six months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)